Demand is no longer the constraint in Australian consumer health — provenance is. Category investment keeps climbing, and the scarce commercial asset has become a product a shopper can verify.
Across 7 June to 7 August 2026 the category's growth signals and its trust signals moved in opposite directions. Nielsen Ad Intel put vitamins and supplements advertising at $75.1 million for the year to 31 May 2026, up 26.5%, concentrated among five incumbent advertisers. In the same eight weeks the TGA cancelled eight of thirteen reviewed listed medicines, confirmed it was still investigating fifteen of sixteen sunscreens that failed CHOICE's SPF testing a year earlier, escalated enforcement against unapproved peptides, and watched a University of Sydney study show more than three million high-dose vitamin B6 packs still moving through the trade a year before rescheduling bites. Meanwhile a legal import loophole let untested supplements reach Australian shoppers directly. Category demand held; the ability to prove what is in the bottle did not.
Growth is coming from basket, not footfall
Fonto's March 2026 quarter put pharmacy retail spend per customer at $219, up 11.6%, with frequency flat. The category is growing on spend per occasion, not on additional trips.
Four compliance fronts opened at once
Sunscreen SPF, high-dose B6, grey-import NMN and unapproved peptides all escalated inside the period. Each erodes the "TGA-regulated" shorthand brands have leaned on for a decade.
Shelf data is becoming a retailer asset
Chemist Warehouse joined the investor register of shelf-intelligence firm Augmodo in July. Woolworths began rationalising branded range under Customer Offer Reset. Both change supplier leverage.
Stop treating compliance as a cost line and start merchandising it. The AUST L number, the trademarked ingredient and the batch certificate are becoming purchase drivers, not legal furniture. Brands that put verification on the front of pack — and retailers that range against it — will take share from the grey channel through spring.
Longevity & Cellular-Health Nutrition
Rising| Trending now | NAD+ precursors moved from niche to contested. Complementary Medicines Australia and Longevity Life Sciences issued a joint consumer warning on 4 Aug about non-compliant NMN sold from overseas websites. |
| Consumer needs | Healthspan, cellular energy, cognitive and metabolic ageing — increasingly framed as prevention rather than anti-ageing. |
| Ingredients / formats | NMN (CellVive is the only TGA-permitted NMN ingredient), nicotinamide, quercetin phytosomes, spermidine, urolithin A; capsule-dominant with premium price architecture. |
| Notable brands | Swisse Nutra (Chemist Warehouse exclusive, launched Oct 2025), Elevate CellVive NMN Advance, a long tail of unlisted offshore sellers. |
| Pharmacy vs grocery | Almost entirely pharmacy and DTC. Grocery has no credible longevity shelf and is unlikely to build one at these price points. |
| Seasonality / timing | Not seasonal, but the New Year resolution cycle is the natural trial window — meaning ranging decisions made now determine January performance. |
| Commercial implication | The category's binding constraint is credibility, not demand. Compliant supply is a moat: brands with an AUST L number and a named ingredient trademark can price against a grey market that cannot legally make the same claims. |
Women's Hormonal Health & Menopause
Rising| Trending now | H&H Group published Australian research on 28 July showing 40% of Australian women lack understanding of what happens during perimenopause and menopause, with a stated preference for VMS over HRT. |
| Consumer needs | Hormonal balance, sleep, mood, cognition and muscle maintenance across the 35–54 window — the ages with strongest stated purchase consideration. |
| Ingredients / formats | Magnesium by form, ashwagandha, vaginal-health probiotics, creatine crossing in from sport, collagen for joint and skin support. |
| Notable brands | JSHealth Menopause+ Support Formula and Swisse Ultiboost Magnesium + Hormone Support both carried "new" flags at Priceline and Swisse's own store during the period. |
| Pharmacy vs grocery | Pharmacy leads decisively — the segment needs a consult, a claim and a considered price. Grocery participation is limited to entry-price magnesium. |
| Seasonality / timing | Not weather-driven, but Women's Health Week (early September) is the single largest AU activation window and sits four weeks after this issue. |
| Commercial implication | Education is the conversion barrier, not price. The 40% knowledge gap is a media brief, not a formulation brief — brands that fund symptom literacy will own the category before it is fully ranged. |
Sports Nutrition, Creatine & Protein
Rising| Trending now | Euromonitor sized high-protein food, drinks and supplements above US$3 trillion in 2025 retail sales on 14 July, and named fibre, creatine and peptides as the leading "post-protein" spaces. |
| Consumer needs | Strength, muscle preservation, recovery and — increasingly — cognition and healthy ageing rather than gym performance alone. |
| Ingredients / formats | Creatine monohydrate (branded: Creapure, CreHytine), whey and pea protein, HMB, electrolytes. Formats diversifying into candy-style chews and RTDs. |
| Notable brands | Bulk Nutrients, True Protein, Bondi Protein Co (Chemist Warehouse owned label), plus women-specific creatine entrants Naternal and Biolae Creatone. |
| Pharmacy vs grocery | Genuinely dual-channel now. Pharmacy holds the health-positioned and women's creatine occasion; grocery holds ambient protein snacking and RTD. |
| Seasonality / timing | Late winter is the pre-season build for the spring and summer fitness cycle; ranging locked in August determines share through the January peak. |
| Commercial implication | Creatine's expansion into women's, cognitive and ageing occasions has outrun the evidence for novel formats. Industry leaders flagged creatine gummies and RTDs as overrated where stability data lags — a formulation warning, not a demand one. |
Cough, Cold, Flu & Respiratory OTC
Softening| Trending now | The 2026 flu season materially under-delivered against 2025. Q1 2026 recorded 25,430 influenza notifications against 48,641 in Q1 2025, and activity remained "low" in NSW and "below expected levels" in Tasmania in mid-July. |
| Consumer needs | Symptom relief, family self-care, and a growing preference for prevention (vaccination in-pharmacy) over treatment. |
| Ingredients / formats | Paracetamol and ibuprofen liquids, benzydamine throat sprays, nasal decongestants; intranasal LAIV flu vaccine now state-funded for children in NSW, QLD, SA and WA. |
| Notable brands | Chemist Warehouse ran a Winter Wellness Week from 16–22 July with Respiratory as one of six named pillars — a promotional response to a soft season. |
| Pharmacy vs grocery | Pharmacy retains scheduled and pharmacist-only lines; grocery holds small-pack analgesics and lozenges. Grocery is more exposed to a soft season because it cannot convert the shopper to a service. |
| Seasonality / timing | The AU cold and flu window is closing. August into September pivots to spring allergy: Victorian grass pollen season runs 1 October to 31 December and Sydney resumes pollen counting on 26 September. |
| Commercial implication | Plan FY27 on a normalised, not a 2025, comp. The commercial opportunity is to move investment forward into the allergy and hay fever reset rather than defend a winter that has already passed. |
Sun Care & Skin Protection
Softening| Trending now | At Senate Estimates on 5 June the TGA confirmed it was still investigating 15 of the 16 sunscreens CHOICE found short of their SPF claims — a year after the original report and with more than 20 products already recalled or paused. |
| Consumer needs | Certainty. Industry body ACCORD publicly warned about the impact of a year-long investigation on consumer confidence in the category. |
| Ingredients / formats | Zinc mineral and cosmetic hybrid SPF are the contested formats; the TGA's March consultation (closed 23 May) proposed lab accreditation, mandatory testing data at listing, and replacing SPF numbers with low/medium/high/very high descriptors. |
| Notable brands | The recall list spans premium and private label alike — Ultra Violette, Cancer Council, Banana Boat, Bondi Sands, Woolworths and Coles own brand all appeared in CHOICE testing. |
| Pharmacy vs grocery | Both are damaged. Neither channel can currently offer a trust-based reason to prefer it, which makes price the default tiebreaker — the worst outcome for a premium-positioned category. |
| Seasonality / timing | Worst possible timing: the spring and summer sun care reset is set in August and September for October shelf. Buyers are ranging into unresolved regulatory uncertainty. |
| Commercial implication | Any brand holding independent, accredited SPF testing data should be publishing it now. First mover on verified testing takes the trust position for an entire summer while competitors wait for the regulator. |
Gut Health, Fibre & Digestive
Rising| Trending now | Fibre is being positioned as the successor to protein. Euromonitor's 14 July analysis put it closest to protein's current usage; The Vitamin Shoppe's 29 June US report showed fibre sales up 20% year-to-date with "psyllium husk" searches up 150%. |
| Consumer needs | Digestive comfort, satiety, immunity and metabolic support — a shift from treating a problem to daily foundational nutrition. |
| Ingredients / formats | Psyllium, inulin, PHGG, postbiotics; powders and gummies gaining on capsules. Swisse listed both a Prebiotic Fibre Powder and Probiotic + Prebiotic Gummies as new during the period. |
| Notable brands | Swisse, Bioglan, JSHealth Greens + Collagen, plus a strong DTC fibre tier (Propel Health, Switch Nutrition) not yet ranged in mass retail. |
| Pharmacy vs grocery | Pharmacy owns the therapeutic and dosed-fibre occasion; grocery owns fibre-fortified food. The two are converging on the same shopper from opposite directions. |
| Seasonality / timing | Gut health peaks in January but builds through spring as the weight-management and "reset" narrative returns; new-format fibre needs to be on shelf by October. |
| Commercial implication | Australia has not yet had its fibre moment at scale. The US signal is strong and the ingredient is cheap, compliant and format-flexible — this is the most under-exploited transferable trend on the board. |
Metabolic & GLP-1 Halo STANDING CARD
Rising| Trending now | Consumer-shelf activity was quieter than the June issue but the underlying economics held. At the Macquarie Australia Conference on 5–6 May Sigma described the GLP-1 uplift in Chemist Warehouse stores as an "enduring benefit", with GLP-1 customer baskets 40% larger in units. Berberine-led metabolic wellness appeared in mainstream pharmacy ranging, with BIOSOURCE Berberine Complex carrying a "new" flag at Priceline. |
| Consumer needs | Muscle preservation during rapid weight loss, satiety, micronutrient repletion under appetite suppression, digestive tolerance, and a self-directed "metabolic wellness" alternative for shoppers not on medication. |
| Ingredients / formats | Whey and pea protein, creatine, HMB, electrolytes, fibre, berberine (including the Berbevis phytosome form). Vitafoods Europe in May showcased protein shots, high-protein/high-fibre bites and choline-fortified formats built explicitly as GLP-1 companions. |
| Notable brands | Global ingredient houses are ahead of Australian brand owners here: Arla, Cargill and ADM all showed GLP-1 companion concepts. No Australian retailer has yet built a dedicated companion set. |
| Pharmacy vs grocery | Pharmacy holds the medicated shopper by definition, and increasingly the companion basket with them. Telehealth verticals continue to bypass both channels entirely — and both the TGA and AHPRA have active scrutiny of weight-loss service advertising and prescribing. |
| Seasonality / timing | The January weight-management peak is the natural launch window, which makes September and October the decision point for range submissions and pack development. |
| Commercial implication | The companion basket is being captured by accident rather than design. A signposted "on your journey" set — protein, creatine, electrolytes, fibre, multivitamin — is a merchandising decision available to any pharmacy banner today, and none has taken it. Drug pipeline, molecules and prescribing are covered in the GLP-1 & Metabolic Watch brief. |
Beauty-from-Within & Derma Skincare
Stable| Trending now | NutraIngredients reported on 31 July that peptides are rising and collagen falling within beauty-from-within, as the segment broadens from hair, skin and nails into wellness territory. On the topical side, Uriage's full range went exclusive to Chemist Warehouse with a promotion opening 3 August. |
| Consumer needs | Barrier repair, sensitive-skin reassurance and visible efficacy — with pharmacy positioned as the credible alternative to both prestige beauty and the grey online market. |
| Ingredients / formats | Marine collagen (Swisse High Strength Marine Collagen+ listed as new), bioactive peptides, ceramides, biotin; shots and powders gaining on tablets. |
| Notable brands | Swisse Beauty, Bioglan Marine Collagen Beauty Shots and JSHealth Greens + Collagen all held "new" flags at Priceline; Uriage anchors the derma-exclusive play at Chemist Warehouse. |
| Pharmacy vs grocery | Firmly pharmacy-led. Grocery participates only in entry-price collagen powders and has no derma credential. |
| Seasonality / timing | Winter dryness is the current hook — Chemist Warehouse ran "Dry Skin Saviours" and "Winter Glow" as Winter Wellness Week pillars in July — before the spring pivot to sun protection and brightening. |
| Commercial implication | Collagen's plateau is a claims problem, not a category problem. Brands should be preparing peptide-led successors now rather than defending collagen share into a segment where consumers are already moving on. |
| Category | Regulatory Pressure |
Grey-Market Leakage |
Claim Fragility |
Consumer Trust Risk |
Demand Momentum |
|---|---|---|---|---|---|
| Sun care & skin protection | Severe | Low | Severe | Severe | Soft |
| Longevity & cellular health | Elevated | Severe | Severe | Elevated | Strong |
| Metabolic & GLP-1 halo | Severe | Severe | Elevated | Elevated | Strong |
| Sports nutrition & creatine | Elevated | Elevated | Elevated | Low | Strong |
| VMS — magnesium & B-group | Severe | Low | Elevated | Elevated | Steady |
| Women's hormonal health | Low | Elevated | Elevated | Low | Strong |
| Gut health & fibre | Low | Low | Low | Low | Strong |
| Cough, cold & flu OTC | Low | Minimal | Low | Low | Soft |
| Dimension | Pharmacy | Grocery |
|---|---|---|
| Momentum | Fonto's March 2026 quarter data put pharmacy retail spend per customer at $219, up 11.6% year-on-year, with growth coming from higher spend per visit rather than more visits. | Growth reweighting toward everyday price. Woolworths' Customer Offer Reset began reducing branded range from late June for an estimated $100–210M in cost-of-goods savings. |
| Category share shift | Taking share in OTC, vitamins, skincare and personal care on price, availability and convenience — the structural migration Fonto identified as pharmacy's dominant growth story. | Losing health and wellness share to pharmacy on the same three attributes, while retaining fibre-fortified and protein-fortified food. |
| Lead retailer dynamic | Chemist Warehouse added 450,000 customers year-on-year in the March quarter with frequency up 7.5%; Priceline lost 340,000 customers with frequency down 1.9%. | Coles and Woolworths both scaling own brand. 68% of 2026 Product of the Year winners came from the two retailers' own ranges, up from 55% a year earlier. |
| Range architecture | Exclusivity is the primary weapon — Uriage full range exclusive from 3 August, Swisse Nutra exclusive since launch, Bondi Protein Co as owned label. | Rationalisation is the primary weapon. Fewer branded lines, deeper own-brand penetration, more everyday-price stability and less promotional depth. |
| Data & supplier leverage | Chemist Warehouse appeared as an investor in shelf-intelligence firm Augmodo's $21M raise on 13 July, deepening a partnership already rolled out across more than 500 stores. | Mature retail media and loyalty data, but shelf-condition data remains largely supplier-reported rather than continuously sensed. |
| Regulatory exposure | High but manageable — pharmacist oversight is an asset when B6 moves to Schedule 3 in June 2027 and when shoppers want provenance advice. | Higher relative risk on sun care and B6: no counter, no consult, and own-brand sunscreens named in the CHOICE testing. |
| Emerging threat | The grey import channel and telehealth verticals, both of which bypass the shelf entirely. | Delivery platforms — grocery's share of delivery-app transactions rose from 14% to 28% between September 2025 and March 2026, changing where health baskets are built. |
Nielsen Ad Intel data released on 7 July 2026 shows advertising spend in Australia's vitamins and supplements sector reached $75.1 million in the 12 months from 1 June 2025 to 31 May 2026, up 26.5% year-on-year. The five highest-spending advertisers were Caruso's Natural Health, Swisse Wellness, Blackmores, Pharm-A-Care Laboratories and Sanofi-Aventis Consumer Health Care.
At Senate Estimates on 5 June 2026 the TGA confirmed it had reached no outcome on 15 of the 16 sunscreens that CHOICE testing found fell short of their labelled SPF, a year after the original report. Seven of those returned SPF results in the 20s despite carrying SPF 50 or 50+ labels. Only Ultra Violette Lean Screen — which tested at SPF 4 — has been resolved, via cancellation and recall alongside 19 products sharing the same base formula. ACCORD chief executive Damian Mitsch said the industry was "concerned about the impact on consumer confidence in sunscreen that a year-long investigation has had".
University of Sydney research published on 31 July 2026 found more than three million products containing 50 mg or more of vitamin B6 were purchased, many of which will be restricted to Pharmacist Only sale from 1 June 2027. Researchers identified high-risk purchasing behaviours including multiple B6 products bought in a single transaction and repeat purchases suggesting prolonged use or stockpiling. Professor Harnett noted that consumers can still exceed the new 50 mg threshold by combining lower-dose products, which the scheduling change does not cover, and warned that the 12-month implementation runway extends the window for stockpiling.
The TGA's June 2026 update to the Listed Medicine Compliance Reports database covered compliance reviews of 13 listed medicines, including products carrying non-permitted health claims about NAD, NAD+, NADH or NMN, alongside claims relating to fertility and preconception health, arthritis, irritable bowel syndrome and inflammatory skin conditions. Following those reviews, eight were cancelled from the Australian Register of Therapeutic Goods and can no longer be supplied. The update follows a March 2026 tranche covering 32 listed medicines, including sunscreens reviewed for lower-than-claimed SPF. Listed medicine advertising is one of the TGA's 12 named priority focus areas for 2026–27.
Seattle spatial-AI firm Augmodo announced a $21 million raise on 13 July 2026 at a $350 million valuation, led by TQ Ventures, with Chemist Warehouse named among the backers alongside Lerer Hippeau, Jefferson River Capital, Arena Holdings and others. Augmodo's Smartbadge wearables passively scan shelves as store associates work, generating a real-time "Realogram" store layout; its SpatialView platform provides retail executives and brand partners with live shelf-condition visibility. Chemist Warehouse ran a pilot from December 2024 and moved to a rollout across more than 500 stores during 2025.
Correction: two details above have since been checked against the primary sources: the pilot began in mid-2024 with four Melbourne stores and was announced that December, and the store figure is a target of more than 550 locations over two years announced on 31 March 2025 — not a rollout completed during 2025.
Australia recorded 25,430 influenza notifications in the first quarter of 2026 against 48,641 in Q1 2025, and the Doherty Institute reported in early May that cases were running at about half the prior-year pace. Immunisation Coalition surveillance for mid-July 2026 showed NSW influenza activity "continued to increase but remained at a low level", Tasmania "low and below expected levels", and Queensland with 12 people hospitalised in the week to 13 July. The 2025 season had been exceptional, extending beyond the usual winter peak on the A/H3N2 Subclade K strain.
Retail Mosaic reported on 25 June 2026 that Woolworths is running a range rationalisation program called Customer Offer Reset, reducing branded range and shifting more products to the Lower Shelf Price everyday-low-price proposition. The analysis estimates a $100–210 million cost-of-goods benefit, notes the program "will show up on shelf shortly" and will impact the next two years, and warns explicitly that it "will alienate some suppliers". Lower Shelf Price itself has been expanding since 2025, with more than 350 products added by the February 2026 result.
Retail Pharmacy magazine reported on 4 August 2026, with follow-up coverage on 5 August, that health experts are urging Australians to avoid buying supplements from overseas websites. NMN is the focal point: CellVive NMN, supplied by Longevity Life Sciences, remains the only NMN ingredient permitted in Australian listed medicines following the TGA's December 2025 permissible-ingredient determination. Dr Teresa Nicoletti noted that offshore sites use phrasing such as "formulated and bottled in Australia" to imply local provenance, and that some make claims extending to preventing conditions such as Alzheimer's disease. CMA chief executive John O'Doherty urged consumers to check for an AUST L number, warning offshore products "will not have the amount of ingredients they claim — sometimes this means it has zero content or dangerously high levels". The regulator had already moved on the same ingredient family: the TGA's June compliance tranche included listings reviewed for non-permitted NAD, NAD+, NADH or NMN claims, four weeks before the industry issued its own warning.
The Australian published an investigation on 2 August 2026 finding that the Personal Importation Scheme — designed to let individuals access medicines from overseas — is being exploited by offshore supplement sellers to sell mislabelled or untested products to Australians, ranging from vitamins to prescription peptides, with targeting practices that are meant to be prohibited. The same day the ABC published a parallel investigation showing injectable peptides including retatrutide and melanotan II being sold openly on Facebook Marketplace, sourced from China and distributed via Australia Post.
NutraIngredients reported on 28 July 2026 on H&H Group research commissioned among 778 Australian women aged 20 and above likely to consider purchasing VMS in the next 12 months. The study found 40% of Australian women lack understanding of what is happening to their body during perimenopause or menopause, and a stated preference for VMS over prescription medicines or HRT. One in three said they would consider purchasing women's health supplements. Women were substantially more likely than men to recognise the benefit of women's VMS on hormonal balance (47% versus 18%), with strongest consideration in the 35–44 and 45–54 age groups.
Euromonitor International published The Age of Proteinmaxxing and the Future of Protein Demand on 14 July 2026, reporting that high-protein food, drinks and supplements generated more than US$3 trillion in retail sales in 2025, with global protein demand projected to rise 11% between 2024 and 2029. Fibre, creatine and peptides were named the leading post-protein spaces, with the report arguing fibre is closest to protein's current usage. The analysis also flagged pressure on the trend: 41% of global adults trying to improve their diet are eating less ultra-processed food, and high-protein ready meals carried an average 66% price mark-up in 2024. Euromonitor's Matthew Barry noted the strongest opportunities lie with "older adults, GLP-1 users, people doing resistance training".
Chemist Warehouse ran a Winter Wellness Week from 16 to 22 July 2026, structured around six named pillars: Oral Care, Dry Skin Saviours, Hair Repair, Curl Care, Winter Glow and Respiratory. The activation was promoted through the retailer's creator network rather than catalogue alone.
Chemist Warehouse promoted the complete Uriage skincare range as exclusive to the retailer, with a promotion opening 6:00pm AEST on Monday 3 August 2026 and the full range valued at $399.85 at everyday low price. Uriage is a French thermal-water derma brand with strong sensitive-skin and barrier-repair positioning.
The TGA formally added unapproved peptide products to its compliance focus areas and issued a warning in June 2026 about serious adverse effects including liver damage, severe allergic reactions requiring hospitalisation and inflammation. In May 2026 it seized almost a million units of illicit pharmaceuticals as part of a global operation that shut 5,700 online sellers, and issued 27 infringement notices plus a fine exceeding $100,000 to a NSW supplier of melanotan II. An April 2026 joint operation with the Australian Border Force and Victoria Police led to three arrests and $2 million in seizures. On 6 August 2026 7NEWS reported on a death linked to years of peptide use, with university researchers finding tested products both underdosed and overdosed.
NutraIngredients' trends round-up of 31 July 2026 reported that the sports performance market has seen a significant wave of 2026 launches shifting toward lifestyle performance, convenient formats and cognitive benefits, with creatine "by far the most dominant ingredient" and brands targeting lifestyle users beyond athletes. Formats are diversifying into candy-style products, foods and beverages. Separately, NielsenIQ, Nutribloom Consulting and Imaraïs Beauty reported that peptides are rising and collagen falling in beauty-from-within as the segment broadens beyond hair, skin and nails. Industry leaders speaking at a NutraIngredients forum on 23 July named creatine gummies and ready-to-drinks among overrated trends "when the stability and data do not yet support the promise".
The Vitamin Shoppe released its 2026 Health and Wellness Trend Report on 29 June 2026, drawing on store and online sales and search data plus a survey of 2,000 US adults. Fibre category sales rose 20% year-to-date, with "fiber" searches up 59% and "psyllium husk" up 150%, and nearly 70% of Americans reporting they are actively trying to increase fibre intake — a movement the retailer attributes partly to TikTok's "fibermaxxing" trend and to GLP-1 nutrition awareness. The report also found searches for branded ingredients such as Creapure and PeptiStrong multiplied by up to 400%, two-thirds of consumers trust trademarked ingredients more than generic alternatives, and 47% decided not to buy a supplement because the label or formula lacked sufficient transparency.
Priceline's site carried "new" flags in early August 2026 on JSHealth Menopause+ Support Formula, JSHealth Deep Sleep+ Nightly Support, JSHealth Greens + Collagen, BIOSOURCE Berberine Complex and Bioglan Marine Collagen Beauty Complex Shots. Swisse's own store simultaneously listed as new: Ultiboost Magnesium + Hormone Support, Magnesium Glycinate Relax with L-Theanine, Vaginal Health Probiotic Gummies, Ashwagandha Gummies, Prebiotic Fibre Powder and Probiotic + Prebiotic Gummies.
NielsenIQ published its Women's Wellness Trends 2026 perspective on 3 August 2026, arguing that women are "spending, self-researching, and switching faster, raising the stakes for credible claims, retention, and need-state growth". It identifies menstruation, fertility, pregnancy, menopause and general health as requiring distinct claims, ingredients, channels and services, and notes growth is moving beyond aisles toward needs such as digestive health, brain health, metabolism and immunity.
Consumer data firm Fonto's March 2026 quarter analysis, reported in trade media on 25 May 2026, found pharmacy retail spend per customer reached $219, up 11.6% year-on-year, with frequency and penetration flat — meaning growth now comes from spend per occasion. Chemist Warehouse added 450,000 customers year-on-year with frequency up 7.5% and basket up 3.9%, reaching $166 spend per customer across roughly 3.5 purchases against a category-average basket of $43, and was shopped by close to half of all Australians aged 18 and over. Priceline lost 340,000 customers with frequency down 1.9%. Grocery's share of delivery-app transactions rose from 14% to 28% between September 2025 and March 2026. [This data predates the report window by a fortnight and is included as the most recent hard channel measurement available; treat as the baseline against which June–August activity should be read.]
[speculative] Reckitt announced on 5 August 2026 that Mucinex 12HR Cold & Fever Multi-Symptom had received FDA approval — the first FDA-approved OTC innovation in the cold and flu category in 14 years, and Reckitt's first New Drug Application approval under its own name. The product treats fever, cough, chest congestion and body pain for 12 hours and is available at US retailers nationwide. No Australian registration application or launch timing has been announced, and the Mucinex brand does not hold the same Australian shelf position it holds in the US.
Merchandise verification as a benefit
Put the AUST L number, the trademarked ingredient name and a batch certificate route on the front of pack and at the shelf edge. CMA has effectively instructed shoppers to check for an AUST L number; two-thirds of consumers in The Vitamin Shoppe's research trust trademarked ingredients over generics, and 47% walked away from a purchase over insufficient label transparency.
Build the menopause literacy shelf
Fund symptom education, not just formulation. H&H Group found 40% of Australian women don't understand what is happening during perimenopause or menopause, with a stated preference for VMS over HRT and one in three willing to consider a women's health supplement. NielsenIQ's 3 August perspective argues the shelf should be organised by life stage rather than ingredient.
Take the verified-SPF position for summer
Any sun care brand holding independent, accredited SPF testing data should publish it now — the test lab, the standard, the result — rather than waiting for the TGA to mandate transparency. ACCORD has publicly acknowledged the damage a year-long investigation has done to consumer confidence, and no brand has yet claimed the verified ground.
Range a signposted GLP-1 companion set
No Australian retailer has built a dedicated GLP-1 companion destination, despite Sigma describing the GLP-1 basket uplift as an enduring benefit with baskets 40% larger in units. The set already exists in range — protein, creatine, electrolytes, fibre and a multivitamin — and needs signposting, adjacency and staff training rather than new product.
Bring fibre to the Australian shelf before the trend arrives
Fibre is cheap, compliant, format-flexible and carries none of the claims fragility attached to longevity or metabolic positioning. Euromonitor put it closest to protein's current usage on 14 July; The Vitamin Shoppe reported US fibre sales up 20% year-to-date with psyllium husk searches up 150%. Australian mass ranging remains thin outside DTC.
Reformulate B6 down and keep general sale
Magnesium, multivitamin and sleep formulations carrying more than 50 mg of vitamin B6 face a binary choice before 1 June 2027: reformulate to 50 mg or below and retain unrestricted distribution including grocery, or move behind the pharmacy counter as Schedule 3 with the volume loss that implies. The reformulation is straightforward; the ranging consequence is not.
| Trend | AU Visibility | Entry Channel | Barriers | Timing |
|---|---|---|---|---|
| Fibre as a foundational category ("fibermaxxing") | Early Strong US retailer data; Australian mass ranging still thin outside DTC and a handful of Swisse and JSHealth lines. | Both — pharmacy for dosed powders, grocery for fortified food and RTD. | Few. Fibre ingredients are permitted, inexpensive and carry low claims risk. The barrier is category management inertia, not regulation. | Spring 2026 ranging for a January 2027 peak. |
| GLP-1 companion nutrition sets | Watch Products are ranged; no Australian retailer has built a signposted destination. Global ingredient houses showcased formats at Vitafoods in May. | Pharmacy — the only channel with the medicated shopper already in store. | Advertising rules limit any explicit reference to prescription medicines, so signposting must be need-state led ("muscle preservation", "appetite support") rather than drug-referential. | September–October range submissions for January. |
| Peptides replacing collagen in beauty-from-within | Watch Reported by NIQ and specialist analysts on 31 July; Australian shelves remain collagen-dominant with peptide claims rare. | Pharmacy and derma skincare; premium DTC first. | Serious reputational adjacency to the injectable peptide grey market currently under TGA enforcement. Permitted-indication constraints also limit claim language. | 2027 shelf, with formulation and naming decisions needed in 2026. |
| Liver health as daily metabolic support | Early US-only signal — The Vitamin Shoppe reported "liver health" searches up 700% and liver cleanse sales nearly doubling. No comparable Australian evidence identified. | Pharmacy VMS, likely alongside metabolic and longevity sets. | Permitted indications for liver claims in Australian listed medicines are narrow. "Detox" and "cleanse" language carries elevated advertising compliance risk. | Watch only — do not treat as an Australian trend without local search or ranging proof. |
| Branded-ingredient trust premium | Visible Already live locally — CellVive NMN is a mandated single-source ingredient, and Creapure and CreHytine are used as differentiators by Australian creatine brands. | Both, but pharmacy realises the price premium. | Ingredient licensing cost and supply exclusivity. Consumer recognition of ingredient trademarks is lower in Australia than the US. | Now — this is the most immediately actionable transfer on the list. |
| Cold & flu OTC pharmaceutical innovation | Early Reckitt's Mucinex 12HR received FDA approval on 5 August — the first US OTC cold and flu innovation in 14 years. No Australian application announced. | Pharmacy, and only after TGA registration as a registered OTC medicine. | Full OTC registration dossier required; the Mucinex brand does not hold an equivalent Australian shelf position. | 2028 at the earliest; overseas watch item only. |
| Whey protein input cost inflation | Watch Suppliers at Vitafoods in May reported unprecedented whey cost rises as manufacturers struggle to meet protein-fortification demand. | Affects every protein-containing SKU across both channels. | Not a demand barrier but a margin one; plant protein substitution changes taste, texture and claims. | Already flowing into FY27 costings — pricing conversations should be happening now. |
- Audit every ranged SKU's ARTG status — eight of thirteen reviewed listings were cancelled in June alone.
- Decide on B6 reformulation now; artwork, stability and ARTG variation lead times consume most of the runway to June 2027.
- Move verification onto the front of pack: AUST L number, ingredient trademark, batch certificate route.
- Extend creatine into non-gym occasions in stable formats only; hold gummies and RTDs until stability data exists.
- Every compliance story this period resolves to a question a pharmacist can answer — build the counter conversation deliberately.
- Build a signposted GLP-1 companion set; the products are already ranged and no banner has claimed the position.
- Reorganise the women's shelf by life stage rather than ingredient, ahead of Women's Health Week in September.
- Non-Chemist Warehouse banners: the price argument is lost. Advice, diagnosis and life-stage curation are the remaining ground.
- Customer Offer Reset delivers real cost benefit but arrives as consumer health demand is fragmenting into segments that reward depth.
- Own-brand health has crossed the trust threshold — 68% of 2026 Product of the Year winners were Coles or Woolworths lines.
- Own-brand sun care carries disproportionate risk while the TGA investigation remains open; ensure independent testing evidence is in hand.
- Fibre-fortified food is the cleanest health growth available to grocery: low claims risk, low cost, high transferable demand.
- Normalise winter respiratory comparatives — 2025 was exceptional and 2026 ran near half its notification volume.
- Model grey-channel leakage explicitly in longevity, metabolic and performance; it is invisible in retailer data.
- Pharmacy category growth is now spend-per-visit, not frequency — shift measurement toward basket composition.
- Treat US retailer sales and search data as directional for Australia and demand local ranging or search proof before acting.
- Chemist Warehouse taking equity in Augmodo signals that shelf-condition data is becoming a retailer-owned asset with supplier-facing revenue.
- A 26.5% rise in category advertising concentrated among five incumbents is share defence — expect margin pressure across mid-tier brands.
- Compliant single-source ingredients such as CellVive NMN create durable, legally protected category positions worth underwriting.
- The regulatory backlog itself is now a sector risk factor: unresolved sunscreen investigations are suppressing an entire category's pricing power.
Sell the proof, not just the benefit
For a decade Australian consumer health brands have competed on need-state and price, treating TGA compliance as a fixed cost of doing business and an invisible one. This period ended that. When a peak body publicly instructs shoppers to check for an AUST L number, when a national newspaper documents untested product arriving through a legal loophole, and when the regulator cancels eight of thirteen listings it reviews, compliance stops being background infrastructure and becomes a visible point of difference. The brands that win the next eighteen months will be the ones that put the evidence on the pack — the registration number, the named ingredient trademark, the accredited testing — and make checking it easy. This costs almost nothing and is available in the next artwork cycle.
Rebase winter and reinvest in spring
The 2026 flu season did not arrive at 2025 intensity, and the numbers make that unambiguous: roughly half the notification volume through the first half of the year, with activity still described as low in the largest states in mid-July. Chemist Warehouse's own Winter Wellness Week gave only one of six pillars to respiratory. The strategic error available here is to read a soft comparative as structural decline and permanently cut winter investment. The better move is to normalise the comparative, hold the winter position, and move discretionary spend forward into the spring allergy reset and the sun care trust vacuum — two categories where the calendar is fixed and the competitive position is genuinely open.
Build portfolios around muscle, hormones and fibre
Three ingredient platforms did the heavy lifting this period, and each serves multiple shopper groups with a single physiological rationale. Creatine now spans sport, menopause, cognition, healthy ageing and GLP-1 companionship. Magnesium sold by form serves sleep, stress, cognition and hormonal support at premium prices. Fibre bridges digestive health, satiety, metabolic wellness and GLP-1 tolerance. Portfolios organised around these platforms get range efficiency and need-state breadth simultaneously — which matters more than usual with Woolworths cutting branded lines and Chemist Warehouse holding real-time visibility of what actually moves.
Treat the grey channel as a competitor, not a compliance problem
The offshore import channel is taking real volume from the fastest-growing segments — longevity, metabolic and performance — and it does not appear in a single retailer's scan data. Enforcement will not solve it, because the TGA's authority stops at goods supplied within Australia and offshore sellers are actively disguising their origin. The commercial answer is competitive rather than regulatory: make the compliant purchase visibly safer, better advised and available in the formats and doses shoppers are going offshore to find. Where a permitted ingredient exists, range it properly. Where it does not, say so plainly rather than leaving shoppers to conclude the category is simply unavailable here.
Assume the retailer knows more than you do
Chemist Warehouse moved from customer to shareholder in the company that measures its shelves, having already rolled the technology across more than 500 stores. Woolworths is running a two-year range rationalisation informed by its own data. In both cases the retailer now holds a continuously updated, granular view of on-shelf reality that suppliers see only in lagged, aggregated form. Brands that negotiate on assertion — about availability, compliance, rate of sale — will increasingly be negotiating against evidence. The response is to get access to that data on commercial terms while it is still being priced as a service, and to build the internal capability to act on it before it becomes a condition of trade.
Pharmacy's advantage this period was regulatory, not promotional. Every compliance story that broke between June and August — sunscreen, B6, NMN, peptides — resolves to a question a pharmacist can answer and a supermarket aisle cannot. Chemist Warehouse's scale means it is simultaneously the biggest beneficiary of that trust premium and the retailer least dependent on it, because its shopper comes for price. The banner that converts the provenance conversation into a service will out-earn the one that only discounts.
Grocery's health play narrowed at exactly the wrong moment. Woolworths' Customer Offer Reset is a rational answer to price trust, but it lands as consumer health demand is fragmenting into need-states that reward range depth, not range efficiency. Retail analysts covering the program have been explicit that it "will alienate some suppliers". Health and wellness brands sitting in the second or third position in a grocery category should assume their line count is under review over the next two years.
The channel question is no longer pharmacy versus grocery — it is regulated shelf versus unregulated screen. Two national investigations published on 2 August described supplements and peptides reaching Australians through an import loophole and social marketplaces. Both channels lose that volume. The commercial response is shared: make the regulated purchase visibly safer, faster and better advised than the offshore alternative, and price the difference honestly.